At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
AGN-229666 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating AGN-229666, Vehicle to AGN-229666, and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 240 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedJun 11, 2014
Enrollment StartJun 4, 2014
Primary CompletionDec 20, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.1 years ago
Interventions
AGN-229666drug
One drop of AGN-229666 in the eye on Days 1 and 15.
Vehicle to AGN-229666drug
One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Olopatadinedrug
One drop of olopatadine in the eye on Days 1 and 15.